Intellect Neurosciences, Inc. Obtains OX1 Phase 1b Draft Report Showing the Company's Lead Alzheimer's Candidate Was Safe and Well-Tolerated at All Dose Levels Tested
27. Oktober 2010 06:30 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Oct. 27, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences Issues Letter to Shareholders
13. Oktober 2010 10:24 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Oct. 13, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences, Inc. Obtains New Patent for Alzheimer Monoclonal Antibodies From the United States Patent and Trademark Office; Milestone Supports Company's Mission to Develop Innovative Disease Modifying Treatments for Alzheimer's Disease
05. Oktober 2010 08:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Oct. 5, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses...
Intellect Neurosciences CEO to Deliver Key Note Speech on the Development of Novel Alzheimer's Therapeutics at Medical Conference in Ireland
20. September 2010 08:48 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with both internal preclinical and clinical-stage pipelines, as well as multiple...
Intellect Neurosciences Launches New Website
14. September 2010 08:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 14, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
Intellect Neurosciences Issues Letter to Shareholders
08. September 2010 08:30 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 8, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Former Head of Discovery Translational Medicine at Wyeth Research and Pfizer Joins Intellect Neurosciences, Inc. as Key Consultant
07. September 2010 08:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 7, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences to Participate in Rodman & Renshaw 2010 Annual Global Investment Conference in New York on September 14, 2010
01. September 2010 09:10 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 1, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences, Inc. CEO Comments on Recent Events in the Development of Novel Alzheimer's Therapies
19. August 2010 15:13 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Aug. 19, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences, Inc. Locks Database for OX1 Phase 1b Clinical Trial
18. August 2010 08:08 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Aug. 18, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...